A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma

Conclusion Conditioning therapy with a lower dose of melphalan, combined with fludarabine, appears to be promising in allogeneic HCT for lymphoma. The Clinicaltrials.gov identification number for the present study is NCT00772811. Micro-Abstract In our phase II trial, we investigated a conditioning regimen of fludarabine and melphalan 100 mg/m2 for allogeneic hematopoietic cell transplantation for lymphoma. The 5-year overall survival rate was 40.4%, and the nonrelapse mortality rate was 21.6%. Patients with severe chronic graft-versus-host disease (GVHD) had greater overall survival than those with no, mild, or moderate chronic GVHD. Conditioning therapy with a lower dose of melphalan, combined with fludarabine, appears to be promising for allogeneic transplantation for lymphoma.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research